NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/30/2024
Back to search
Official data from USPTO
C CYCLACEL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
01/30/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
09/29/2022
Registration date
01/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/30/2024
Last transaction
01/30/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
11
Owner location
London, GB
Examiner
CALLAGHAN, BRIAN P
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word CYCLACEL shown in black with a highly stylized letter C comprised of five curved bands shown in light blue with seven black graduated dots.
Holders and representatives
Holders
Cyclacel Limited
Representatives
JEFFREY A. SMITH MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical substances and preparations for the treatment of cancerhematological disorders; pharmaceutical substances and preparations for use in oncologyhematology; medical preparations for the treatment of cancer and hematological disorders; medical substances in the nature of pharmaceuticals for the treatment of oncological diseases and preparations for use in oncology; medicinal preparations for the treatment of cancer and hematological disorders; medical substances in the nature of pharmaceuticals for the treatment of cancer and hematological disorders; pharmaceutical preparations for human use for the treatment of cancer and hematological disorders
Class 42
Pharmaceutical development; pharmaceutical products development; development of pharmaceuticals for the treatment of cancer; development of products for the treatment of cancer; development of pharmaceuticals for the treatment of leukemia; development of pharmaceuticals for the treatment of hematological cancers; development of products for the treatment of leukemia; development of products for the treatment of hematological cancers
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/30/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/14/2023
PUBO
PUBLISHED FOR OPPOSITION
11/14/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/25/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/06/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
10/06/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/06/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
10/06/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/21/2023
GNRT
NON-FINAL ACTION E-MAILED
07/21/2023
CNRT
NON-FINAL ACTION WRITTEN
07/21/2023
DOCK
ASSIGNED TO EXAMINER
07/13/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/17/2022
NWAP
NEW APPLICATION ENTERED
10/03/2022
Continuous trademark protection
Get notified about every new filing that threatens C CYCLACEL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.